Kypha discovers, develops and commercializes innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space, with potential implications including detecting the onset of adverse events earlier, optimizing treatment sooner, predicting outcomes more accurately, and managing disease and patient more effectively. The company's platform facilitates testing at scale from home health to the clinical laboratories helping detect the onset of adverse events earlier and optimizing treatment sooner, enabling patients to have a higher chance of favorable health outcomes.